Literature DB >> 19005025

Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.

F S Sarfo1, R O Phillips, E Ampadu, F Sarpong, E Adentwe, M Wansbrough-Jones.   

Abstract

We have studied the evolution of the gamma interferon (IFN-gamma) and interleukin 10 (IL-10) responses after Mycobacterium ulcerans sonicate stimulation of whole blood from patients with early M. ulcerans lesions during treatment with rifampin and streptomycin for 8 weeks. Among the 26 patients, secretion of IFN-gamma increased during treatment, with a significant increase at 4 weeks and a further increase after 8 weeks overall. The increase was more rapid in patients with large or ulcerative lesions, becoming significant by 4 weeks. For small lesions, there was only a minor increase, which did not reach significance. There was no significant change in the median IL-10 response during antibiotic therapy, and there was no inverse correlation between IFN-gamma and IL-10 responses. These results demonstrate that an IFN-gamma secretory response to M. ulcerans developed, independently of IL-10 secretion, in patients whose M. ulcerans disease healed during antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005025      PMCID: PMC2620668          DOI: 10.1128/CVI.00235-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  24 in total

1.  A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells.

Authors:  K M George; L Pascopella; D M Welty; P L Small
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine.

Authors:  W D Revill; R H Morrow; M C Pike; J Ateng
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

3.  Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity.

Authors:  D H Hsu; K W Moore; H Spits
Journal:  Int Immunol       Date:  1992-05       Impact factor: 4.823

4.  Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts.

Authors:  Travis M Gooding; Paul D R Johnson; May Smith; Andrew S Kemp; Roy M Robins-Browne
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

5.  Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans.

Authors:  Timothy P Stinear; Armand Mve-Obiang; Pamela L C Small; Wafa Frigui; Melinda J Pryor; Roland Brosch; Grant A Jenkin; Paul D R Johnson; John K Davies; Richard E Lee; Sarojini Adusumilli; Thierry Garnier; Stephen F Haydock; Peter F Leadlay; Stewart T Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-21       Impact factor: 11.205

6.  Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.

Authors:  Ghislaine Prévot; Eliane Bourreau; Herve Pascalis; Roger Pradinaud; Audrey Tanghe; Kris Huygen; Pascal Launois
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 7.  Dynamics of cytokine generation in patients with active pulmonary tuberculosis.

Authors:  Eun-Kyeong Jo; Jeong-Kyu Park; Hazel M Dockrell
Journal:  Curr Opin Infect Dis       Date:  2003-06       Impact factor: 4.915

8.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Authors:  D F Fiorentino; A Zlotnik; P Vieira; T R Mosmann; M Howard; K W Moore; A O'Garra
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

9.  An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease.

Authors:  M R Evans; R Phillips; S N Etuaful; G Amofah; J Adomako; O Adjei; J Dennis-Antwi; S B Lucas; M H Wansbrough-Jones
Journal:  Trans R Soc Trop Med Hyg       Date:  2003 Mar-Apr       Impact factor: 2.184

10.  Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin.

Authors:  Daniela Schütte; Alphonse Um-Boock; Ernestina Mensah-Quainoo; Peter Itin; Peter Schmid; Gerd Pluschke
Journal:  PLoS Negl Trop Dis       Date:  2007-10-31
View more
  12 in total

Review 1.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

2.  Serum levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection.

Authors:  Janine de Zeeuw; Sridevi Duggirala; Willemien A Nienhuis; K Mohammed Abass; Wilson Tuah; Till F Omansen; Tjip S van der Werf; Ymkje Stienstra
Journal:  Am J Trop Med Hyg       Date:  2013-07-08       Impact factor: 2.345

3.  In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Authors:  Till F Omansen; Renee A Marcsisin; Brendon Y Chua; Weiguang Zeng; David C Jackson; Jessica L Porter; Ymkje Stienstra; Tjip S van der Werf; Timothy P Stinear
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

4.  Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.

Authors:  Fred S Sarfo; Fabien Le Chevalier; N'Guetta Aka; Richard O Phillips; Yaw Amoako; Ivo G Boneca; Pascal Lenormand; Mireille Dosso; Mark Wansbrough-Jones; Romain Veyron-Churlet; Laure Guenin-Macé; Caroline Demangel
Journal:  PLoS Negl Trop Dis       Date:  2011-07-19

5.  Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection.

Authors:  Teresa G Martins; José B Gama; Alexandra G Fraga; Margarida Saraiva; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

6.  Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections.

Authors:  Daniel P O'Brien; Mike Robson; N Deborah Friedman; Aaron Walton; Anthony McDonald; Peter Callan; Andrew Hughes; Richard Rahdon; Eugene Athan
Journal:  BMC Infect Dis       Date:  2013-09-05       Impact factor: 3.090

7.  Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.

Authors:  Saraswoti Khadge; Sayera Banu; Kidist Bobosha; Jolien J van der Ploeg-van Schip; Isabela M Goulart; Pratibha Thapa; Chhatra B Kunwar; Krista E van Meijgaarden; Susan J F van den Eeden; Louis Wilson; Senjuti Kabir; Hymonti Dey; Luiz R Goulart; Janaina Lobato; Washington Carvalho; Yonas Bekele; Kees L M C Franken; Abraham Aseffa; John S Spencer; Linda Oskam; Tom H M Otttenhoff; Deanna A Hagge; Annemieke Geluk
Journal:  BMC Infect Dis       Date:  2015-10-28       Impact factor: 3.090

8.  Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue.

Authors:  Fred Stephen Sarfo; Richard O Phillips; Brian Rangers; Engy A Mahrous; Richard E Lee; Edward Tarelli; Kingsley B Asiedu; Pamela L Small; Mark H Wansbrough-Jones
Journal:  PLoS Negl Trop Dis       Date:  2010-01-05

Review 9.  Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Mark Wansbrough-Jones; Rachel E Simmonds
Journal:  Cell Microbiol       Date:  2016-01       Impact factor: 3.715

10.  Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.

Authors:  Mabel Sarpong-Duah; Michael Frimpong; Marcus Beissner; Malkin Saar; Ken Laing; Francisca Sarpong; Aloysius Dzigbordi Loglo; Kabiru Mohammed Abass; Margaret Frempong; Fred Stephen Sarfo; Gisela Bretzel; Mark Wansbrough-Jones; Richard Odame Phillips
Journal:  PLoS Negl Trop Dis       Date:  2017-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.